idalopirdine   Click here for help

GtoPdb Ligand ID: 8689

Synonyms: compound 52 [4] | Lu AE58054 | LU-AE58054
Compound class: Synthetic organic
Comment: Idalopirdine is a serotonin 5-HT6 receptor antagonist [4].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 1
Hydrogen bond donors 2
Rotatable bonds 9
Topological polar surface area 37.05
Molecular weight 398.14
XLogP 5.38
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES Fc1ccc2c(c1)[nH]cc2CCNCc1cccc(c1)OCC(C(F)F)(F)F
Isomeric SMILES Fc1ccc2c(c1)[nH]cc2CCNCc1cccc(c1)OCC(C(F)F)(F)F
InChI InChI=1S/C20H19F5N2O/c21-15-4-5-17-14(11-27-18(17)9-15)6-7-26-10-13-2-1-3-16(8-13)28-12-20(24,25)19(22)23/h1-5,8-9,11,19,26-27H,6-7,10,12H2
InChI Key YBAWYTYNMZWMMJ-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Idalopirdine reached Phase 2I clinical trial as a potential augmentation therapy for the treatment of the cognitive deficits associated with Alzheimer's disease (AD) [2], being assessed in patients with mild-moderate AD who were receiving donepezil therapy. Wilkinson et al. (2014) reported encouraging results from the earlier Phase 2 trial [6]. However, the developer, Lundbeck, reported failure of the first of three Phase 2I studies (STARSHINE) to meet primary and secondary endpoints (Sept 2016), and failure of its two other Phase 2I trials (STARBEAM and STARBRIGHT) to show efficacy (Feb 2017), and that they were therefore not submitting idalopirdine for regulatory approval.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
5-HT6 receptor antagonists have been reported to improve cognitive deficit [5], and are being investigated as a novel mechanism to treat the cognitive impairment which develops in AD [1,3].